Nextgen Share Discussion Threads

[lady gaga] 06/6/2011 08:54

As auston would say yea baby yea

[lady gaga] 06/6/2011 08:42

Nice another 5% jump come on baby lol

[lady gaga] 06/6/2011 08:31

No-one letting them go.

She should jump another 10% plus soon.

Glta

LG

[lady gaga] 06/6/2011 08:26

Looking quite healthy.

A nice little move.

Come on NGG

[lady gaga] 29/5/2011 15:15

Yea normally news late friday is bad news but this is pretty good.

Losses have reduced also.

[bobby.ifa] 29/5/2011 15:11

It seemed an odd time to release the results & news.

[lady gaga] 29/5/2011 14:18

The bit I like.

All info nice and clear concise.

A company who knows exactly what it wants to achieve.

Current trading and outlook
 
In 2010 NextGen Sciences established a business strategy focused on biomarker discovery and biomarker qualification (through the development of MRM based quantitative assays). To underpin this strategy the company has restructured both its management and operational teams at the Ann Arbor facility to ensure it can meet the challenges of delivering product to the standard required by its customers.
 
During 2010 the company continued to offer and perform services for pharma, biotech and academic customers in the USA, EU and Japan.
 
In Q4 of 2010 the company commenced the development of two biomarker assay panels (the human plasma was launched in April 2011 and human CSF will be launched in Q2 of 2011 respectively).
 
These assays will serve a number of purposes:
 
1.   They will demonstrate to the market place that NextGen Sciences is able to develop technically validated, quantitative MRM assays for biomarker discovery and qualification. This will attract revenue through custom assay development and testing projects or assay transfer projects (assays developed by the customers) from the customer to NextGen Sciences.
 
2.   They will enable NextGen Sciences to build market traction and brand awareness in the field of Oncology diseases through the human plasma assay. This will bring near term revenues through testing of samples against the plasma assay. This will also attract custom assay development projects and opportunities for NextGen Sciences to become involved in co-development opportunities in the Oncology disease area.
 
3.   They will enable NextGen Sciences to build market traction and brand awareness in the field of CNS disease through the human CSF assay. This will bring near term revenues through
 
testing of samples against the plasma assay. This will also attract custom assay development projects and opportunities for NextGen Sciences to become involved in co-development opportunities in the CNS disease area.
 
4.   They will drive the growth of our biomarker discovery services since these services can be the first step in selecting potential biomarkers for which MRM assays can be developed to enable biomarker qualification.
 
NextGen Sciences believes that it is vital for the growth of the business that it continues to deploy resources as available, to the development of therapeutically relevant assay panels (plasma and CSF). This will enable the company to focus on specific market segments to attract samples for biomarker testing as a highly scalable and profitable business element.
 
NextGen Sciences all believe that this approach will offer the potential to become involved in co-development (co-investment) projects for the discovery and qualification of biomarkers that could serve as diagnostics. This could open up new avenues for the business to pursue in the diagnostic and personalised healthcare space.

We should get a good reaction when markets reopen.
Not many seen this Friday evening.


Glta

Lg

[lady gaga] 29/5/2011 14:00

Results out late Friday evening.

Anyone see them.

[lady gaga] 25/5/2011 11:05

Weve got a plug here.

It looks like Tom likes us.

The discovery that points to biotech's incredible revival...

(This article first appeared in Penny Sleuth on 10 February 2011. Penny Sleuth is an unregulated free e-letter written by Tom Bulford and published by MoneyWeek Limited)



2010 was the year of the junior miner.

Every week saw some plucky explorer score unbelievable gains. But this year is likely to be different, and I've got my eye on a few other sectors that I think could see fantastic successes in 2011.

I've talked about food stocks and the remarkable recovery in UK manufacturing. But one sector that is really beginning to look exciting is biotech.

Dormant for years and abandoned by investors as a non-starter, biotech looks to be on the cusp of a thrilling revival. After a string of dramatic announcements in recent months, it seems that investors have discovered a newfound enthusiasm for these stocks.

Just look at what happened this week when drug researcher SAREUM HOLDINGS (SAR) revealed news of another exciting breakthrough...



The discovery that points to Biotech's extraordinary revival

On Monday Dr Tim Mitchell, Chief Executive of the Cambridge based drug researcher, reported that its Aurora+FLT3 Kinase programme had, in a pre-clinical in-vivo study, appeared to slow the progress of cancer.

Ten leukaemia patients were treated with this compound and their 'leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated'. By contrast for those who did not receive Sareum's compound their leukaemia 'increased five to fifteen fold'.

That was enough to send Sareum's share price multiplying. Having drifted along for months at a price of about 0.25p, the shares took off, hitting 1.65p the following day and 4.79p on Wednesday. It has slipped back a little today. But those lucky enough to have been holding the shares and smart enough to have got out at the top could have multiplied their money nineteen-fold in the space of just three days.

No less impressive was the extraordinary volume of shares that were traded. On Wednesday 1,142,362,883 Sareum shares were traded, representing over 80% of its entire issued capital, and the excitement spread elsewhere.

• Oxford-based PHYSIOMICS (PYC) has developed a simulation platform that can show how a tumour will react to drug exposure. It saw its share price surge from 0.25p to an intra-day high of 0.68p

• The US company NEXTGEN (NGG), which offers a suite of services that can increase the traditionally low success rates associated with biomarker development, flew from 0.11p to a high of 0.53p

• VALIRX (VAL), which focuses on the epigenomic analysis and treatment of cancer (the epigenome consists of chemical compounds that modify, or mark, the genome in a way that tells it what to do) almost doubled to 0.53p

This is an extraordinary revival for a sector that has been languishing for so long that most investors have given it up. But you need to be very careful here...




A sector shot through with risk - and scintillating rewards

A cure for cancer is the equivalent of finding a river of liquid gold. But still, the biotech industry is fraught with danger. It eats up money, and genuine successes are few and far between.

A few years ago high hopes were held for ANTISOMA (ASM), also a company looking for successful cancer drugs. This week it was described as a company 'that develops drugs that do not work'. That's a harsh but fair verdict on a company that has seen its share price sink from 36p to 2.2p over the last twelve months.

Those who rushed into Sareum are already being brought face to face with some of the realities of biotech life. Today the company took advantage of the surge of interest to tap shareholders for £500,000, through the sale of 500m new shares at a penny a time.

And a more careful reading of Sareum's Monday revelation shows that 'at six weeks following treatment, no detectable cancer could be found in two of the ten examples dosed with the Sareum compound. In the remaining eight treated examples, the average time taken for the leukaemia to increase five-fold was six weeks, compared to two weeks in the untreated cases'. So while Sareum's treatment seems to have some advantages over others, it appears to limit the spread of cancer, rather than kill it off completely.

How marvellous it would be if Sareum had a cancer cure! But shareholders should prepare for a long and bumpy ride. Biotech research is a laborious process. While successful developments in this area often improve upon existing therapies, few provide a total cure.

In time Sareum will need to find licensing partners, most probably big pharma companies with deep pockets. As big pharma cuts back on its own research spending, it is increasingly looking for small biotechs to do the early work, but the big boys do not move fast.

[the_doctor] 20/5/2011 12:29

Gaga - it's telling that rather than give any reasons WHY this should rise, you just harp back to some story about PYC

You seem to think these microcaps will just double and double for no reason
The brief hype spikes are finished

[lady gaga] 18/5/2011 12:49

Ure sounding desperate for shares doctor.

By the way PYC look poised to rocket soon.

Thats a tip for u by the way.

The last time I told u 2 buy PYC they were .30p now .63p.


The next stop will be 1.25p in my view.


So buy buy buy.

Also im topping up here on weakness.

[the_doctor] 18/5/2011 08:38

bobby - hardly surprising given that not one poster can explain to me how NGG would make some money. I didnt ask the question to deramp, but because I was genuinely intrigued as to what people are anticipating.

I can only think that the micro-bio hot money squad pumped it up?
but I'm open to other views of anyone has any (ie. not silly comments from Lady Gaga)

[bobby.ifa] 18/5/2011 08:18

Looking gloomy guys, selling pressure taking us down. No news for a while, can see us back in the 0.15 range at this rate.

[the_doctor] 16/5/2011 09:23

Lady Gaga, you can make all the silly comments, but cant answer my questions.

Like I said, you're clearly just a ramper that has no clue about the prospects

[lady gaga] 15/5/2011 21:36

7 years in school and u still know nothing,

7 mins more like.

lol

[the_doctor] 13/5/2011 15:41

Lady Gaga, you can make all the silly comments, but cant answer my questions.

Like I said, you're clearly just a ramper that has no clue about the prospects

[lady gaga] 13/5/2011 13:17

Theres only 1 name for u and it ant doctor.

lol

[the_doctor] 13/5/2011 12:35

'who dream up login names 2 make them feel important'

eh? It was a nickname long before I came on advfn

so come on, why are you struggling to answer the questions I put forward?

I've looked through the RNSs, I've looked at what NextGen has to offer.
But I dont see why you expect the business to generate a profit?

[lady gaga] 13/5/2011 12:28

And b ware of clowns like the doctor who dream up login names 2 make them feel important.

He who questioned me in PYC at .3p and now trading at .63p.

Its killing him.

Ps

more updated due here soon.

Read past rns released.

Im not going to post them for u.

GLTA

LG

[the_doctor] 13/5/2011 12:21

I never get any answers to this
I suspect because most here are just out to ramp a microstock, hoping that an influx of PIs will shift it up, rather than having any clue about the business

New readers here - beware of posts from people like Lady Gaga

If people cant explain why NGG should be a success, take their positive views with a BIG pinch of salt


the_doctor - 13 May'11 - 09:12 - 207 of 216 edit

Please could someone explain what/how much you expect to come from Summ?
To me, NextGen is like PRM but without the main value-drivers
Constructive views detailing how NGG is to make money welcomed

[lady gaga] 13/5/2011 12:09

Summ has taken off again.

Lets hope they return. lol

[bobby.ifa] 13/5/2011 10:03

Spoke to soon.

[sakamuka] 13/5/2011 10:02

No problem Bobby, yes indeed they...we are!
;-)

[bobby.ifa] 13/5/2011 09:58

Thanks Sakamuka, makes sense now.All micro-Bio's up this morning. Quite incestuous lot, aren't they?